Global animal health company Vimian Group has reported another strong quarter, with revenue and operating earnings rising at a double-digit pace during the second quarter of 2026. The company credited broad-based demand across its four business segments, continued product innovation and strategic acquisitions for its performance. However, higher financing costs and working capital investments continued to weigh on net earnings and cash flow.
The Sweden-based company generated €121.6 million in revenue, representing a 17% increase compared with the same quarter last year. Organic growth reached 12%, outperforming the broader global animal health market, while acquisitions contributed another six percentage points to reported growth. Currency movements had a small negative impact on reported sales.
Strong Performance Across All Business Segments
Vimian operates through four specialist businesses—Specialty Pharma, MedTech, Veterinary Services and Diagnostics—and each recorded double-digit organic growth during the quarter.
The company’s adjusted EBITA increased 17% to €29.7 million, while the adjusted EBITA margin improved slightly to 24.5%, reflecting better operating efficiency and stronger profitability within its MedTech business. Operating profit (EBIT) climbed 54% to €22.3 million, highlighting improved operational execution across the organisation.
Chief Executive Officer Alireza Tajbakhsh said the company delivered growth ahead of the overall animal health market while maintaining strong momentum across all four operating divisions.
Product Innovation Continues to Fuel Expansion
Innovation remained one of Vimian’s biggest growth drivers during the quarter. According to the company’s investor presentation, Vimian launched 75 new products over the past twelve months and currently has more than 60 additional products under development.
Among the notable developments were:
-
Expansion of the PAX2 veterinary allergy testing platform
-
Continued progress of the Nextmune Bio biologics platform
-
Launch of IryLac ophthalmic products
-
Introduction of UNA 10 gut health supplements
-
Ongoing expansion into new veterinary therapeutic categories and international markets.
These investments strengthen Vimian’s position in high-growth areas such as veterinary allergy management, companion animal nutrition, diagnostics and biologic therapies.
MedTech Business Shows Strong Recovery
One of the standout performers during the quarter was Vimian’s MedTech division, which returned to double-digit organic growth after a softer performance in previous periods.
Revenue from MedTech increased to €43.3 million, while adjusted EBITA grew 27%. The improvement was supported by stronger veterinary dental sales, operational improvements in the U.S. orthopaedics business and contributions from recent acquisitions. International orthopaedics also recorded two consecutive quarters of double-digit growth across Europe and Asia-Pacific.
Acquisitions Continue to Support Growth Strategy
Acquisitions remain an important part of Vimian’s long-term strategy.
Management confirmed that its acquisition pipeline remains active across all four business segments. During 2026, the company has continued adding specialist veterinary businesses that expand its geographic reach and strengthen its product portfolio. These acquisitions contributed meaningfully to second-quarter revenue growth while supporting future expansion opportunities.
Higher Financial Costs Limit Bottom-Line Growth
While operating performance remained strong, higher financing expenses reduced growth in net profit. Profit for the quarter reached €8.8 million, broadly unchanged from the previous year, while earnings per share remained at €0.02.
The company reported that higher interest expenses, foreign exchange effects and adjustments related to financial liabilities increased total net financial costs during the quarter. Operating cash flow also declined compared with the previous year as inventories and receivables increased to support business expansion.
Sustainability Recognition Strengthens Corporate Profile
Beyond financial performance, Vimian also achieved an important sustainability milestone.
The company announced that its MSCI ESG rating was upgraded to AAA, placing it among the highest-rated healthcare equipment and supplies companies globally. Management believes sustainability, innovation and responsible business practices remain central to its long-term growth strategy.
What This Means for the Animal Health Industry
Vimian’s latest results highlight several trends shaping the global animal health industry:
-
Continued demand for specialised veterinary medicines and diagnostics.
-
Growing investment in companion animal healthcare.
-
Increasing adoption of advanced veterinary MedTech solutions.
-
Ongoing consolidation through strategic acquisitions.
-
Strong emphasis on product innovation and biologics.
These trends are expected to continue supporting long-term growth across veterinary pharmaceuticals, diagnostics and medical technology as demand for advanced animal healthcare solutions rises worldwide.
Key Q2 2026 Highlights – Copy of Investor Presentation Q2′ 2026 vimian q2 2026 financial report
-
Revenue increased 17% to €121.6 million.
-
Organic growth reached 12%.
-
Adjusted EBITA rose 17% to €29.7 million.
-
EBIT margin improved to 24.5%.
-
All four business segments delivered double-digit organic growth.
-
More than 75 new products launched over the past year.
-
Over 60 products remain in the development pipeline.
-
Active acquisition pipeline continues across all business segments.
-
MSCI ESG rating upgraded to AAA
